Tafinlar/Mekinist (dabrafenib/trametinib)

pCPA File Number: 21132
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Novartis Pharmaceuticals Canada Inc.
CDA-AMC Project Number:
pCODR 10152
pCPA Engagement Letter Issued:
Negotiation Process Concluded: